N-acetylcysteine (NAC) nebulizer therapy is effective and safe as a short-term (12-week) treatment for reducing phlegm in chronic obstructive pulmonary disease (COPD), according to study findings ...

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), with a ...

High-intensity noninvasive positive pressure ventilation (NPPV) might have reduced need for endotracheal intubation for ...

GOLD COPD Report includes updated research and recommendations that reflect shifts in thinking on COPD management.

Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies: Paris Wednesday, September 11, 2024, 16:00 Hrs [IST] A pooled analysis from ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, shares the latest clinical discoveries from the BOREAS trial on type 2 inflammation in patients with chronic ...

Famed filmmaker David Lynch, 78, says that while he loved everything about smoking, he stopped two years ago after being ...

ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies Pooled results from the BOREAS and NOTUS studies show meaningful clinical benefit ...

DirectRx pharmacy was added to the network of pharmacies distributing newly approved COPD therapy Ohtuvayre (ensifentrine) in ...

Ensifentrine (Ohtuvayre) acts as bronchodilator and non-steroidal anti-inflammatory agent. It is formulated as suspension for inhalational route of administration. Ohtuvayre is indicated for the ...

AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary ...